Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non-Current Liabilities (2016 - 2018)

Fennec Pharmaceuticals' Other Non-Current Liabilities history spans 8 years, with the latest figure at $167000.0 for Q2 2018.

  • For the quarter ending Q2 2018, Other Non-Current Liabilities rose 206.37% year-over-year to $167000.0, compared with a TTM value of $167000.0 through Jun 2018, up 206.37%, and an annual FY2017 reading of $167000.0, up 406.06% over the prior year.
  • Other Non-Current Liabilities for Q2 2018 was $167000.0 at Fennec Pharmaceuticals, roughly flat from $167000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $5.5 million in Q1 2014, with the low at -$157000.0 in Q2 2017.
  • Average Other Non-Current Liabilities over 5 years is $1.2 million, with a median of $167000.0 recorded in 2017.
  • Year-over-year, Other Non-Current Liabilities soared 2342.59% in 2014 and then crashed 97.34% in 2015.
  • Tracing FENC's Other Non-Current Liabilities over 5 years: stood at $1.3 million in 2014, then crashed by 93.78% to $82000.0 in 2015, then crashed by 59.76% to $33000.0 in 2016, then skyrocketed by 406.06% to $167000.0 in 2017, then changed by 0.0% to $167000.0 in 2018.
  • Per Business Quant, the three most recent readings for FENC's Other Non-Current Liabilities are $167000.0 (Q2 2018), $167000.0 (Q4 2017), and -$157000.0 (Q2 2017).